BEIJING, April 22, 2026 /PRNewswire/ — Dayspring Pharma today announced top-line data from its Phase II clinical trial of CG2001 foam in male patients with androgenetic alopecia (AGA). The trial met its primary endpoint and demonstrated statistically significant and clinically meaningful results, with a favorable efficacy and safety profile.

This multicenter, randomized, double-blind, placebo-controlled Phase II study enrolled 110 Chinese adult men with AGA. Led by Peking University People’s Hospital, the 30-week trial was designed to evaluate the efficacy of CG2001 and identify the recommended dosing regimen for Phase III development.

Key Findings
All CG2001 treatment groups demonstrated a markedly superior improvement trend compared to the placebo group at Week 24. Most notably, the group receiving 5% minoxidil + 0.075% finasteride twice daily demonstrated the best efficacy. Compared with other registered clinical data, including published data from existing Chinese minoxidil foam studies, efficacy improved by approximately 50%. In addition, the treatment showed a rapid onset of action, surpassing the peak efficacy reported in comparator studies as early as Week 12.

In terms of safety, CG2001 was well tolerated and exhibited extremely low systemic exposure. All adverse reactions observed during the study were mild, mainly pruritus and increased scaliness, and resolved spontaneously without medical intervention.

Based on the overall Phase II results, CG2001 has demonstrated strong potential in efficacy, rapid onset of action, and safety. Dayspring Pharma will continue to advance the Phase III clinical development of CG2001, further accelerate its research and translational efforts in hair health, and strive to bring patients more effective and accessible treatment options.

About CG2001
CG2001 is a topical combination of minoxidil and finasteride developed to harness the synergistic potential of two cornerstone therapies for androgenetic alopecia (AGA). Both are widely recognized as first-line treatments for male pattern hair loss: minoxidil promotes hair growth, while finasteride inhibits 5α-reductase and reduces dihydrotestosterone (DHT) levels.

CG2001 is formulated as a specifically designed foam with an optimized dose ratio and delivery system to improve local follicular delivery, enhance efficacy, and minimize systemic exposure associated with oral finasteride.

About Dayspring Pharma
Dayspring Pharma is a pharmaceutical company focused on innovation in dermatology and hair health. The company develops differentiated therapies to address unmet clinical needs. For more information, please visit dayspringpharma.com.

CONTACT: chenguang@dayspringpharma.com 

An estimated ~14.7% weight loss at 18 months was achieved in one of the first studies evaluating integrated GLP-1 therapies and digital coaching in a multi-ethnic Asian population (n=708). This matched gold-standard clinical trial results, with digital coaching acting as a measurable multiplier.

SINGAPORE, April 22, 2026 /PRNewswire/ — GLP-1 medications are transforming obesity treatment, but real-world results consistently fall short of clinical trial outcomes, which sits at around 9% at 12 months, well below the 15% reported in landmark trials like STEP 1, largely due to high discontinuation rates, suboptimal dosing, and lack of structured behavioral support.

A new peer-reviewed study, published in the International Journal of Obesity (Springer Nature), shows that NOVI Health has effectively closed that gap.

The study, conducted in collaboration with the Saw Swee Hock School of Public Health at the National University of Singapore (NUS SSHSPH), evaluated 708 adults enrolled in NOVI Optimum Plus, a physician-led obesity care program that integrates GLP-1 receptor agonist medications with app-based digital coaching and personalized lifestyle support.

The headline result: an estimated ~12.7% mean weight loss at 12 months and ~14.7% at 18 months, on par with results from clinical trials, and significantly above typical real-world GLP-1 outcomes.

Medication Alone is Not Enough

The study makes clear that medication alone is not enough. Participants who actively engaged with NOVI’s digital platform achieved meaningfully better outcomes:

• 2.0to2.2percentagepointsofadditionalweightloss compared to low engagers, equivalent to roughly 15% greater relative weight loss
• ~0.72kg/m²greaterBMIreduction
• Upto2.9mmHgadditionalsystolicbloodpressurereduction

Not All Patients Respond the Same

The study’s multi-ethnic cohort (approximately 45% East Asian, 27% European, 13% South Asian, 10% Southeast Asian) revealed significant variation in treatment response. East Asian participants and individuals with hyperglycemia experienced comparatively lower weight loss, while European and mixed-ethnicity participants achieved greater reductions.

“A one-size-fits-all approach to GLP-1 prescribing does not work in Asia,” said Dr. Sue-Anne Toh, co-founder and Medical Director of NOVI Health, Adjunct Associate Professor at NUS Yong Loo Lin School of Medicine, and the study’s senior author. “Different metabolic profiles and ethnic backgrounds demand a tailored approach. That is exactly what our hybrid model is designed to deliver.”

Broader Metabolic Improvements

Over the study period, participants also experienced:

• Systolicbloodpressure decreased by ~12 mmHg
• Bodyfatpercentage reduced by ~9%
• Waist-to-hipratio improved from 0.83 to 0.80 (model-adjusted estimates)
• HbA1c declined by ~0.6%

About NOVI Health

NOVI Health is a technology-enabled preventive and metabolic health company headquartered in Singapore. NOVI serves a diverse, multi-ethnic patient population across weight care, metabolic health, and longevity programs.

For more information, visit www.novi-health.com or follow @novihealth on Instagram and LinkedIn.

This four-part series explores a fresh perspective on sustainability, showing how care for the
environment and the world is an intuitive, lifelong value, instilled at a young age.

SINGAPORE, April 22, 2026 /PRNewswire/ — AIA Singapore today launched a four-part short film series exploring sustainability through the perspective of children. By capturing their curiosity, imagination, and understanding of the world, the series brings a fresh and relatable lens to a topic often seen as complex and reveals a powerful insight: the values that underpin sustainability are deeply intuitive and understood even by the youngest among us.

Through playful interactions and candid conversations with children aged between 6 to 12, the series reveals how simple and approachable sustainability can be – showing that the instinct to care for the environment is deeply rooted in human nature, while offering a fresh perspective. At the heart of the series, the children remind Singaporeans that the foundations of sustainability are instinctive and already within us, inspiring viewers to embrace these values and contribute to a more sustainable world.

“Sustainability can often feel overwhelming, but the values behind it – caring for our environment, protecting life, reducing waste, and practicing inclusion – are simple and intrinsic,” said Liu Chunyen, Chief Investment Officer of AIA Singapore. 

“Seeing the world through a child’s eyes reconnects us with the simple, significant values we often overlook as adults. It is up to all of us to nurture these values today so that our future generations can carry them forward and shape the world we live in. At AIA Singapore, nurturing these instincts today is central to our commitment to helping people live Healthier, Longer, Better Lives.”

Across four episodes, the series follows children as they explore different dimensions of sustainability through authentic and spontaneous moments of play and conversation:

• Protecting the Planet: Through simple moments connecting with nature, children reflect on caring for the world around them – offering a reminder that an appreciation for our planet often begins at a young age.

• Upcycle Into a New Future: With imagination and creativity, children explore new possibilities for everyday materials, highlighting how fresh perspectives can inspire more thoughtful ways of using and reusing the resources around us. This approach not only encourages innovative upcycling but also fosters a circular mindset – where materials are continually repurposed and given new life, rather than discarded.

• Protecting Biodiversity, Protecting Life: As children share their thoughts about animals and the natural world, their reflections underscore the importance of safeguarding biodiversity and caring for all life forms.

• Upholding Inclusion: Working together toward a shared goal, children demonstrate how embracing different perspectives can help build a world where everyone has a place and a voice.

The short-film series is released today and through the year across AIA Singapore’s social media channels. Watch the first short film, “Protecting the Planet,” here: https://youtu.be/V0Lw64dm0Y8?si=dfTSxjN48SQS0jwH

Sustaining Healthier, Longer, Better Lives

This short film series is AIA Singapore’s latest initiative to drive broader sustainability efforts, as the company continues to champion a sustainable future and safeguard the world for the next generation.

In July 2025, AIA Singapore published its inaugural AIA Sustainability Report 2024, outlining progress across five strategic pillars: Health & Wellness, Sustainable Investment, Sustainable Operations, People & Culture, and Effective Governance. The report reaffirmed how sustainability considerations are embedded across enterprise strategy and investment decision-making and was recognised with a bronze award for Asia’s Best Sustainability Report (First Time) at the Asia Sustainability Reporting Awards.

AIA Singapore seeks to create long-term value through sustainable investments, active engagement, and a focus on the AIA Group’s net-zero goals. In 2022, AIA Singapore launched the AIA Sustainable Multi-Thematic Fund, the first bespoke sustainable thematic fund in Singapore designed for investment-linked products (ILPs).

AIA Singapore’s focus remains on actions that create long-term value, enhance customer outcomes, and strengthen the resilience of the people and communities it serves.

– END –

About AIA   

AIA Group Limited and its subsidiaries (collectively “AIA” or the “Group”) comprise the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets – wholly-owned branches and subsidiaries in Mainland China, Hong Kong SAR^[1], Thailand, Singapore, Malaysia, Australia, Cambodia, Indonesia, Myanmar, New Zealand, the Philippines, South Korea, Sri Lanka, Taiwan (China), Vietnam, Brunei and Macau SAR^[2], and a 49 per cent joint venture in India. In addition, AIA has a 24.99 per cent shareholding in China Post Life Insurance Co., Ltd.

The business that is now AIA was first established in Shanghai more than a century ago in 1919. It is a market leader in Asia (ex-Japan) based on life insurance premiums and holds leading positions across the majority of its markets. It had total assets of US$345 billion as of 31 December 2025.

AIA meets the long-term savings and protection needs of individuals by offering a range of products and services including life insurance, accident and health insurance and savings plans. The Group also provides employee benefits, credit life and pension services to corporate clients. Through an extensive network of agents, partners and employees across Asia, AIA serves the holders of more than 44 million individual policies and over 16 million participating members of group insurance schemes.

AIA Group Limited is listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock codes “1299” for HKD counter and “81299” for RMB counter with American Depositary Receipts (Level 1) traded on the over-the-counter market under the ticker symbol “AAGIY”.